SG Americas Securities LLC Acquires 240,039 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

SG Americas Securities LLC grew its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 1,017.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 263,625 shares of the company’s stock after purchasing an additional 240,039 shares during the period. SG Americas Securities LLC’s holdings in Centessa Pharmaceuticals were worth $6,593,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of CNTA. Tudor Investment Corp ET AL lifted its position in shares of Centessa Pharmaceuticals by 13.7% during the 3rd quarter. Tudor Investment Corp ET AL now owns 57,810 shares of the company’s stock worth $1,402,000 after buying an additional 6,959 shares during the period. TCG Crossover Management LLC grew its position in Centessa Pharmaceuticals by 8.5% in the third quarter. TCG Crossover Management LLC now owns 3,136,480 shares of the company’s stock valued at $76,060,000 after acquiring an additional 245,664 shares during the period. Verition Fund Management LLC acquired a new position in Centessa Pharmaceuticals during the third quarter worth $2,772,000. Jain Global LLC bought a new position in shares of Centessa Pharmaceuticals during the third quarter valued at $5,868,000. Finally, HighVista Strategies LLC lifted its holdings in shares of Centessa Pharmaceuticals by 55.6% during the third quarter. HighVista Strategies LLC now owns 63,301 shares of the company’s stock valued at $1,535,000 after acquiring an additional 22,617 shares during the period. 82.01% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Iqbal J. Hussain sold 38,951 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the sale, the insider directly owned 57,645 shares in the company, valued at $1,449,771.75. This trade represents a 40.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Karen M. Anderson sold 120,029 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $26.25, for a total value of $3,150,761.25. Following the sale, the insider directly owned 62,085 shares of the company’s stock, valued at $1,629,731.25. This represents a 65.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 349,073 shares of company stock worth $9,429,412 over the last 90 days. Insiders own 7.09% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CNTA shares. Needham & Company LLC reiterated a “hold” rating on shares of Centessa Pharmaceuticals in a research report on Tuesday. Truist Financial boosted their price target on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Wolfe Research reaffirmed a “peer perform” rating on shares of Centessa Pharmaceuticals in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Finally, TD Cowen reissued a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Centessa Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

Centessa Pharmaceuticals Stock Up 44.0%

NASDAQ:CNTA opened at $39.72 on Wednesday. The company has a market cap of $5.80 billion, a price-to-earnings ratio of -21.70 and a beta of 1.55. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The stock’s fifty day moving average price is $26.29 and its two-hundred day moving average price is $25.24. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.60 and a 52-week high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, March 31st. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.10). On average, analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Key Stories Impacting Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa for $38 per share in cash plus a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at roughly $6.3B up front and up to $7.8B including milestones; the transaction is framed as an expansion of Lilly’s neuroscience/sleep‑medicine pipeline. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Deal terms include the $38 cash upfront plus CVR milestones (up to $9) — investors are pricing some or all of the CVR into CNTA shares, which helps explain the stock trading above the $38 cash figure. Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
• Positive Sentiment: Unusual options activity: large jump in call buying (nearly 3,000 calls traded, a ~472% spike vs. normal), signaling short‑term bullish speculation or hedging around the deal news.
• Neutral Sentiment: Analysts have mostly left ratings unchanged (Wolfe Research “peer perform”, Needham “hold”), suggesting the deal changes valuation more than near‑term fundamentals. Analyst coverage updates
• Neutral Sentiment: Trading metrics: unusually high share volume and CNTA trading near its 12‑month high, driven by the acquisition announcement and attendant positioning flows.
• Negative Sentiment: Shareholder litigation/investigations have been filed or announced (Ademi Firm and Halper Sadeh LLC) alleging Centessa shareholders may not be getting a fair price, which could lead to legal review, delay or pressure on deal terms. Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.